Welcome everybody to todays hybrid hearing. Pursuant to house rules, some members will appear in person and others will appear remotely via webx. Some members are appearing in person. Let me first remind everyone that pursuant to the latest guidance from the attending physician, all individuals attending the hearing in person must wear a face mask unless you are speaking. Members not wearing a face mask will not be recognized. Let me also make a few reminders for these members appearing in person. You will only see members and witnesses appearing remotely on the monitor in front of you when they are speaking in what is known as webx as active speaker view. The timer is visible in the room directly in front of you. For members appearing remotely, i know you are all familiar with webx by now, but let me remind you of a few points. First, you will be able to see each person speaking during the hearing, whether they are in person or remote, as long as you have your webx set to active speak
Twopart hearing with drug company leaders. It is three hours 35 minutes. Welcome to todays hybrid hearing pursuant to House Speaker rules some members will appear in person and others will appearer remotely. Some members are appearing in person, let me first remind everyone that pursuant to the latest guidance of the house attending physician, all individuals attending this hearing and person must wear a face mask, unless you are speaking. Members whono are not wearing a face mask will not be recognize recognized. Let me also make a few reminders for these members appearing in person. You will only see members and witnesses appearing remotely on the monitor in front of you. When they are speaking and what is known as web act as active speaker view. A timer is visible in theib room directly in front of you. For members appearing know youre all familiar with web ex by now, but let me remind you of a few points. Whether they are in person or remote song as they have their web ex set to ac
Bristol Myers Squibb has announced that it will present data on CAMZYOS (mavacamten) for NYHA class II-III obstructive hypertrophic cardiomyopathy at the American College of Cardiology (ACC) Annual Scientific Session & Expo, ACC.24, taking place April 6-8, 2024 in Atlanta, Georgia.
The approval is based on the pivotal TRIDENT-1 trial, in which Augtyro successfully achieved a high objective response rate and durable response1
Augtyro adds to Bristol Myers Squibb’s growing.